Known targets — ChEMBL curated mechanism
S1PR1S1PR2S1PR3S1PR4S1PR5rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 known ✓ | O95977 | 1/20 | 0.38 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 known ✓ | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 known ✓ | Q9H228 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 10/20 | 0.52 |
| ▸ | CA2 | P00918 | 10/20 | 0.52 |
| ▸ | CA9 | Q16790 | 8/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | CA3 | P07451 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | CA6 | P23280 | 2/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7886279 | 0.92 | CA1 (0.47) | CA1CA2CA9CA12CA7 | |
| SCHEMBL4407987 | 0.86 | CA1 (0.52) | CA1CA2CA9CA12CA7 | |
| SCHEMBL4407930 | 0.86 | CA1 (0.52) | CA1CA2CA9CA12CA7 | |
| SCHEMBL3288211 | 0.86 | CA1 (0.55) | CA1CA2CA9CA12CA7 | |
| Octadecyl Sulfate SCHEMBL11573315 | 0.86 | CA1 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL11572349 | 0.86 | CA1 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL428327 | 0.85 | CA1 (0.59) | CA1CA2CA9CA12CA7 | |
| Alcohol SCHEMBL11428503 | 0.85 | CA1 (0.57) | CA1CA2CA9CA12CA7 | |
| Alcohol SCHEMBL3995143 | 0.85 | CA1 (0.57) | CA1CA2CA9CA12CA7 | |
| Alcohol SCHEMBL6536457 | 0.85 | CA1 (0.57) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200246449-A1 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME | NANOBIO CORPORATION (US) | 2020-08-06 | — | — | US | claimed |
| US-20180095082-A1 | THERMOCHEMICAL-BASED ANTIBODY INACTIVATION METHODS AND SYSTEMS | VENTANA MEDICAL SYSTEMS, INC. | 2018-04-05 | — | — | US | claimed |
| EP-3283881-A1 | THERMOCHEMICAL-BASED ANTIBODY INACTIVATION METHODS AND SYSTEMS | Ventana Medical Systems, Inc. (US) | 2018-02-21 | — | — | EP | claimed |
| WO-2016166073-A1 | THERMOCHEMICAL-BASED ANTIBODY INACTIVATION METHODS AND SYSTEMS | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-10-20 | — | — | WO | claimed |
| EP-1863348-B1 | CELL PERMEABILIZATION AND STABILIZATION REAGENT AND METHOD OF USE | BECKMAN COULTER INC (US) | 2016-10-12 | — | — | EP | claimed |
| US-9145481-B2 | Porous inorganic/organic hybrid materials with ordered domains for chromatographic separations and processes for their preparation | WATERS TECHNOLOGIES CORPORATION (US) | 2015-09-29 | — | — | US | claimed |
| US-20140329919-A1 | POROUS INORGANIC/ORGANIC HYBRID MATERIALS WITH ORDERED DOMAINS FOR CHROMATOGRAPHIC SEPARATIONS AND PROCESSES FOR THEIR PREPARATION | WATERS TECHNOLOGIES CORPORATION (US) | 2014-11-06 | — | — | US | claimed |
| US-20130011443-A1 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE | NANOBIO CORPORATION | 2013-01-10 | — | — | US | claimed |
| US-20120276182-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2012-11-01 | — | — | US | claimed |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2012-08-30 | — | — | US | claimed |
| US-20050260186-A1 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases | HALOZYME, INC. (US) | 2005-11-24 | — | — | US | claimed |
| US-20040268425-A1 | use to treat glycosaminoglycan associated pathologies such as eye disorders or tumors; sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes; transgenic animals; dosage forms | DELIATROPH PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | claimed |
| JP-2004538468-A | — | — | 2004-12-24 | — | — | JP | claimed |
| US-20040191854-A1 | Papanicolau staining process | CYTYC CORPORATION | 2004-09-30 | — | — | US | claimed |
| WO-2004078140-A2 | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | HALOZYME, INC. (US) | 2004-09-16 | — | — | WO | claimed |
| EP-1450924-A1 | POROUS INORGANIC/ORGANIC HYBRID PARTICLES FOR CHROMATOGRAPHIC SEPARATIONS AND PROCESS FOR THEIR PREPARATION | Waters Investments Limited (US) | 2004-09-01 | — | — | EP | claimed |
| EP-1417366-A1 | POROUS INORGANIC/ORGANIC HYBRID MONOLITH MATERIALS FOR CHROMATOGRAPHIC SEPARATIONS AND PROCESS FOR THEIR PREPARATION | Waters Investments Limited (US) | 2004-05-12 | — | — | EP | claimed |
| US-20030150811-A1 | Porous inorganic/organic hybrid monolith materials for chromatographic separations and process for their preparation | WATERS INVESTMENTS LIMITED (US) | 2003-08-14 | — | — | US | claimed |
| WO-2003022392-A1 | POROUS INORGANIC/ORGANIC HYBRID PARTICLES FOR CHROMATOGRAPHIC SEPARATIONS AND PROCESS FOR THEIR PREPARATION | WATERS INVESTMENTS LIMITED (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2003014450-A1 | POROUS INORGANIC/ORGANIC HYBRID MONOLITH MATERIALS FOR CHROMATOGRAPHIC SEPARATIONS AND PROCESS FOR THEIR PREPARATION | WATERS INVESTMENTS LIMITED (US) | 2003-02-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | S1PR4 208/4885S1PR1 137/4885S1PR3 69/4885 |
| US-20120276182-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | S1PR4 420/4885S1PR1 212/4885S1PR3 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.